Kyverna Therapeutics (KYTX) Institutional Ownership → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free KYTX Stock Alerts $15.42 +0.17 (+1.11%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Institutional Ownership Changes (13F Filings) for Kyverna Therapeutics (NASDAQ:KYTX)CurrentInstitutional OwnershipPercentage18.08%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$178.32MNumber ofInstitutional Sellers(last 12 months)0 Get KYTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Kyverna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data KYTX Institutional Buying and Selling by Quarter Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. Kyverna Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/17/2024 Artal Group S.A.200,000$4.97M0.1%N/A0.464% 5/16/2024 Janus Henderson Group PLC606,500$15.04M0.0%N/A1.407% 5/16/2024 Bain Capital Life Sciences Investors LLC3,163,868$78.59M6.3%N/A7.338% 5/16/2024 Blackstone Inc.100,000$2.48M0.0%N/A0.232% 5/15/2024 Price T Rowe Associates Inc. MD929,634$23.09M0.0%N/A2.156% 5/15/2024 Avoro Capital Advisors LLC475,000$11.80M0.1%N/A1.102% 5/14/2024 StemPoint Capital LP41,000$1.02M0.3%N/A0.095% 5/10/2024 Vanguard Group Inc.264,215$6.56M0.0%N/A0.613% 5/2/2024 Jennison Associates LLC1,398,659$34.74M0.0%N/A3.244% (Data available from 1/1/2016 forward) KYTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KYTX shares? During the previous two years, 9 institutional investors and hedge funds held shares of Kyverna Therapeutics. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($78.59M), Jennison Associates LLC ($34.74M), Price T Rowe Associates Inc. MD ($23.09M), Janus Henderson Group PLC ($15.04M), Avoro Capital Advisors LLC ($11.80M), Vanguard Group Inc. ($6.56M), and Artal Group S.A. ($4.97M).Learn more on KYTX's institutional investors. What percentage of Kyverna Therapeutics stock is owned by institutional investors? 18.08% of Kyverna Therapeutics stock is owned by institutional investors. Learn more on KYTX's institutional investor holdings. Which institutional investors have been buying Kyverna Therapeutics stock? Of the 9 institutional investors that purchased Kyverna Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($3.16M), Jennison Associates LLC ($1.40M), Price T Rowe Associates Inc. MD ($929.63K), Janus Henderson Group PLC ($606.50K), Avoro Capital Advisors LLC ($475K), Vanguard Group Inc. ($264.22K), and Artal Group S.A. ($200K). How much institutional buying is happening at Kyverna Therapeutics? Institutional investors have bought a total of 7,178,876 shares in the last 24 months. This purchase volume represents approximately $178.32M in transactions. Related Companies: ITOS Major Shareholders EXAI Major Shareholders VALN Major Shareholders CABA Major Shareholders HLVX Major Shareholders TSHA Major Shareholders ADPT Major Shareholders HUMA Major Shareholders ALEC Major Shareholders RGNX Major Shareholders This page (NASDAQ:KYTX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
